受强制性开放获取政策约束的文章 - Marianna Silletta了解详情
可在其他位置公开访问的文章：6 篇
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
M Rimini, L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, ...
ESMO open 7 (6), 100591, 2022
强制性开放获取政策： Cancer Research UK
Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials
CAM Fulgenzi, B Scheiner, J Korolewicz, CV Stikas, A Gennari, ...
JHEP Reports 5 (5), 100702, 2023
强制性开放获取政策： Cancer Research UK, National Institute for Health Research, UK, Wellcome …
Immunotherapy in hepatocellular carcinoma
CAM Fulgenzi, T Talbot, SM Murray, M Silletta, B Vincenzi, A Cortellini, ...
Current Treatment Options in Oncology 22, 1-19, 2021
强制性开放获取政策： National Institute for Health Research, UK, Wellcome Trust
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
L Balcar, B Scheiner, CAM Fulgenzi, A D’Alessio, K Pomej, MB Roig, ...
JHEP reports 6 (2), 100982, 2024
强制性开放获取政策： Cancer Research UK
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumours (mGISTs)
D Fanale, L Incorvaia, G Badalamenti, JL Iovanna, D Olive, I De Luca, ...
Annals of Oncology 30, v701, 2019
强制性开放获取政策： National Institute of Health and Medical Research, France
Second-line Treatment Patterns and Outcomes in Advanced HCC after Progression on Atezolizumab/Bevacizumab☆
M Wu, CAM Fulgenzi, A D’Alessio, A Cortellini, C Celsa, GF Manfredi, ...
JHEP Reports, 101232, 2024
强制性开放获取政策： Cancer Research UK, National Institute for Health Research, UK
出版信息和资助信息由计算机程序自动确定